BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 22986611)

  • 1. A retrospective analysis of cytogenetic and clinical characteristics in patients with multiple myeloma.
    He J; Yang L; Meng X; Wei G; Wu W; Han X; Zheng G; Zheng W; Ye X; Shi J; Xie W; Zhang J; Huang H; Lin M; Cai Z
    Am J Med Sci; 2013 Feb; 345(2):88-93. PubMed ID: 22986611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.
    Chen L; Li J; Xu W; Qiu H; Zhu Y; Zhang Y; Duan L; Qian S; Lu H
    Exp Oncol; 2007 Jun; 29(2):116-20. PubMed ID: 17704743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cytogenetic study on 53 patients with multiple myeloma].
    Jing Y; Fang MY; Jiang F; Lin S; Wang FT
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):68-72. PubMed ID: 21362224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The significances of 13q14 deletion for development and prognosis of multiple myeloma].
    Li Q; An G; Li CW; Xu Y; Deng SH; Liu XP; Qi JY; Wang YF; Zou DH; Zhao YZ; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2011 Apr; 32(4):217-20. PubMed ID: 21569701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma.
    Königsberg R; Zojer N; Ackermann J; Krömer E; Kittler H; Fritz E; Kaufmann H; Nösslinger T; Riedl L; Gisslinger H; Jäger U; Simonitsch I; Heinz R; Ludwig H; Huber H; Drach J
    J Clin Oncol; 2000 Feb; 18(4):804-12. PubMed ID: 10673522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative study of genetic aberrations in human multiple myeloma cell lines and newly diagnosed MM by fluorescence in situ hybridization].
    An G; Xie ZQ; Li CH; Li Q; Yi SH; Qiu LG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1505-10. PubMed ID: 21176360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular cytogenetic aberrations in Tunisian patients with multiple myeloma identified by cIg-FISH in fixed bone marrow cells.
    Gmidène A; Avet-Loiseau H; Sennana H; Ben Abdallah I; Khlif A; Meddeb B; Elloumi M; Saad A
    Cytogenet Genome Res; 2012; 136(1):44-9. PubMed ID: 22188899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China.
    Lai YY; Huang XJ; Cai Z; Cao XS; Chen FP; Chen XQ; Chen BA; Fang MY; Feng JF; Fu WL; Guo HY; Hou M; Hou J; Hu Y; Hu XT; Hu XM; Huang LQ; Jin J; Li JY; Li J; Li W; Liang YM; Liu T; Liu QF; Liu YH; Mao P; Ouyang J; Qiu LG; Qiu L; Shao CK; Shi B; Song YP; Sun ZM; Wang QS; Wang C; Wang JM; Wang YS; Wang Z; Wu JB; Wu YX; Xia RX; Xue YQ; Yang BZ; Yang G; Yang ZL; Yu L; Yuan Z; Zhang S; Zhang Y; Zhao HG; Zhao L; Zhou DB; Zou SH; Zhu YF
    Chin Med J (Engl); 2012 Aug; 125(15):2663-70. PubMed ID: 22931972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorescence in situ hybridization analysis of chromosome aberrations in 60 Chinese patients with multiple myeloma.
    Gao X; Li C; Zhang R; Yang R; Qu X; Qiu H; Xu J; Lu H; Li J; Chen L
    Med Oncol; 2012 Sep; 29(3):2200-6. PubMed ID: 21611837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.
    Sagaster V; Ludwig H; Kaufmann H; Odelga V; Zojer N; Ackermann J; Küenburg E; Wieser R; Zielinski C; Drach J
    Leukemia; 2007 Jan; 21(1):164-8. PubMed ID: 17096015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorescent in situ hybridization studies in multiple myeloma.
    Yuregir OO; Sahin FI; Yilmaz Z; Kizilkilic E; Karakus S; Ozdogu H
    Hematology; 2009 Apr; 14(2):90-4. PubMed ID: 19298720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Influence of immunomagnetic sorting on detecting genetic aberration of multiple myeloma cells by interphase fluorescence in situ hybridization].
    An G; Li CW; Li Q; Yi SH; Liu XP; Xu Y; Li ZJ; Qi JY; Zou DH; Qiu LG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):54-8. PubMed ID: 21362221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization are complementary techniques to detect cytogenetic abnormalities in multiple myeloma.
    Alpar D; de Jong D; Holczer-Nagy Z; Kajtar B; Savola S; Jakso P; David M; Kosztolanyi S; Kereskai L; Pajor L; Szuhai K
    Genes Chromosomes Cancer; 2013 Sep; 52(9):785-93. PubMed ID: 23720363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Correlation of chromosomal aberrations with prognostic markers in multiple myeloma patients--a single institution study].
    Lee JW; Lee JK; Hong YJ; Hong SI; Chang YH
    Korean J Lab Med; 2008 Dec; 28(6):413-8. PubMed ID: 19127104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fluorescence in situ hybridization identifies complex chromosomal aberrations in multiple myeloma].
    Liu SY; Huang JW; Zhang J; Du HP; Jiang H; Li JY; Xue YQ
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Dec; 24(6):685-8. PubMed ID: 18067084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Application of fluorescence in-situ hybridization technique in multiple myeloma].
    Zhao Y; Zheng D; Li J; Zhu WT
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 Sep; 38(5):459-64. PubMed ID: 19830857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
    Grzasko N; Hus M; Pluta A; Jurczyszyn A; Walter-Croneck A; Morawska M; Chocholska S; Hajek R; Dmoszynska A
    Hematol Oncol; 2013 Mar; 31(1):41-8. PubMed ID: 22674819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.
    Chang H; Trieu Y; Qi X; Xu W; Stewart KA; Reece D
    Leuk Res; 2007 Jun; 31(6):779-82. PubMed ID: 16996589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
    Smetana J; Berankova K; Zaoralova R; Nemec P; Greslikova H; Kupska R; Mikulasova A; Frohlich J; Sevcikova S; Zahradova L; Krejci M; Sandecka V; Almasi M; Kaisarova P; Melicharova H; Adam Z; Penka M; Jarkovsky J; Jurczyszyn A; Hajek R; Kuglik P
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):123-30. PubMed ID: 23291040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The comparison of three cytogenetic methods for detecting multiple myeloma].
    Ren J; Yang LH; Li GX; Fan JL; Hou J
    Zhonghua Nei Ke Za Zhi; 2009 Sep; 48(9):737-40. PubMed ID: 20079209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.